Collegium Pharmaceutical Inc (COLL)vsViatris Inc (VTRS)
COLL
Collegium Pharmaceutical Inc
$33.25
+0.06%
HEALTHCARE · Cap: $1.06B
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1732% more annual revenue ($14.30B vs $780.57M). COLL leads profitability with a 8.1% profit margin vs -24.6%. COLL earns a higher WallStSmart Score of 65/100 (B-).
COLL
Strong Buy65
out of 100
Grade: B-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.2%
Fair Value
$80.96
Current Price
$33.25
$47.71 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 30.0%
Every $100 of equity generates 24 in profit
Earnings expanding 31.5% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Operating Margin, Return on Equity, EPS Growth. Revenue growth of 12.9% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : COLL
The primary concerns for COLL are Market Cap.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
COLL profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
COLL is growing revenue faster at 12.9% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
COLL scores higher overall (65/100 vs 50/100) and 12.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?